GlassScriptPhysician profile
Sunilkumar K Kakadia
NPI 1689921017
$31,295.47
in general payments reported to CMS, 2019-2025
59 companies · $5,517 in 2025
The $5,517 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $397 · 2022: $1,574 · 2023: $16K · 2024: $8,045 · 2025: $5,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $8,261 · Consulting Fee: $5,066 · Honoraria: $1,008 · Travel and Lodging: $280 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,610.00 |
| Food and Beverage | $8,261.01 |
| Consulting Fee | $5,066.00 |
| Honoraria | $1,008.00 |
| Travel and Lodging | $280.43 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $10,860.84 | 2022-2025 | Tagrisso, Imfinzi, Enhertu |
| Pfizer INC. | $3,341.94 | 2022-2025 | |
| Janssen Biotech, INC. | $2,249.22 | 2022-2025 | Darzalex, Erleada, Rybrevant |
| Astellas Pharma US INC | $1,989.08 | 2023-2025 | Padcev, Xospata |
| Pharmacosmos Therapeutics INC. | $1,382.60 | 2023-2025 | Monoferric |
| Incyte Corporation | $1,266.82 | 2022-2025 | Jakafi |
| Karyopharm Therapeutics INC. | $1,127.94 | 2023-2025 | Xpovio |
| Blueprint Medicines Corporation | $1,042.38 | 2023-2024 | Ayvakit |
| Genzyme Corporation | $1,007.57 | 2022-2025 | |
| Myriad Genetic Laboratories, INC. | $778.99 | 2023-2025 | Myrisk |
| Novartis Pharmaceuticals Corporation | $691.61 | 2022-2025 | |
| Lilly USA, LLC | $490.17 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Merck Sharp & Dohme LLC | $418.98 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $393.55 | 2023-2025 | |
| Celgene Corporation | $357.34 | 2022-2025 | Reblozyl, Pomalyst |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $317.67 | 2023-2024 | Orgovyx |
| Glaxosmithkline, LLC. | $303.33 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Dendreon Pharmaceuticals LLC | $295.79 | 2023-2024 | Provenge |
| Eisai INC. | $274.28 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $239.88 | 2023-2025 | Onivyde, Somatuline Depot, Tazverik |
| Emd Serono, INC. | $215.42 | 2023-2025 | Bavencio |
| Daiichi Sankyo INC. | $211.01 | 2023-2025 | Enhertu |
| Exelixis INC. | $209.08 | 2023-2025 | Cabometyx |
| Beigene USA, INC. | $194.22 | 2022-2024 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $190.14 | 2022-2025 | Ninlaro, Fruzaqla, Iclusig |
| Regeneron Healthcare Solutions, INC. | $158.97 | 2023-2025 | Libtayo |
| Seagen INC. | $123.27 | 2023-2025 | Padcev |
| Pharmacyclics LLC, An Abbvie Company | $105.63 | 2022-2023 | Imbruvica, Epkinly |
| Mirati Therapeutics, INC. | $88.85 | 2023-2024 | Krazati |
| Rigel Pharmaceuticals, INC. | $75.19 | 2023-2024 | Tavalisse, Rezlidhia |
| Alnylam Pharmaceuticals INC. | $72.70 | 2022 | |
| Gilead Sciences, INC. | $60.51 | 2024-2025 | Trodelvy |
| Urogen Pharma, INC. | $54.87 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.72 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.68 | 2023-2025 | Gilotrif |
| E.R. Squibb & Sons, L.L.C. | $49.51 | 2023 | Reblozyl, Opdivo |
| Kite Pharma, INC. | $49.33 | 2023 | Yescarta |
| Aveo Pharmaceuticals, INC. | $39.01 | 2025 | |
| Beone Medicines USA, INC. | $38.47 | 2025 | Tevimbra, Brukinsa |
| Stemline Therapeutics INC. | $36.64 | 2023-2024 | Orserdu |
| Array Biopharma INC | $35.79 | 2022-2025 | Braftovi |
| Janssen Scientific Affairs, LLC | $33.62 | 2022 | |
| Iovance Biotherapeutics, INC. | $31.65 | 2025 | Amtagvi |
| Genentech USA, INC. | $30.87 | 2022-2023 | Alecensa, Tecentriq, Gavreto |
| Recordati_rare_diseases_inc. | $25.40 | 2024 | Sylvant |
| Immunogen, INC. | $23.92 | 2023 | Elahere |
| Cti Biopharma Corp. | $21.55 | 2023 | Vonjo |
| Azurity Pharmaceuticals, INC. | $21.51 | 2025 | Danziten, Vivimusta |
| Adc Therapeutics America, INC. | $20.79 | 2023 | |
| Acrotech Biopharma INC. | $20.28 | 2024 | Beleodaq |
| Adaptive Biotechnologies Corporation | $20.07 | 2023 | Clonoseq |
| Amgen INC. | $19.33 | 2022 | |
| Shield Therapeutics INC | $18.80 | 2024 | |
| Pharmaessentia USA Corporation | $16.09 | 2022 | |
| Jazz Pharmaceuticals INC. | $16.00 | 2025 | |
| Puma Biotechnology, INC. | $15.09 | 2023 | |
| G1 Therapeutics, INC. | $15.03 | 2023 | Cosela |
| Heron Therapeutics, INC. | $4.48 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunilkumar Kakadia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.